Literature DB >> 10710060

Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.

R Dresner-Pollak1, F Karmeli, R Eliakim, Z Ackerman, D Rachmilewitz.   

Abstract

OBJECTIVE: Reduced bone mineral density (BMD) is common in patients with inflammatory bowel disease (IBD), but the factors associated with its longitudinal rate of change have not been established. We prospectively assessed the rate of change in BMD, and its association with biochemical markers of bone turnover.
METHODS: Twenty-two patients with Crohn's disease and 14 ulcerative colitis patients age 37.1 +/- 11.6 yr were followed for 2 yr. Lumbar spine (L2-L4) and femoral neck BMD were measured by dual x-ray absorptiometry at baseline and 24 months. Bone-specific alkaline phosphatase, osteocalcin, urinary N-telopeptide crosslinked type 1 collagen (NTx), parathyroid hormone, and 25-hydroxyvitamin-D were determined at baseline.
RESULTS: At baseline, 59% of Crohn's patients and 43% of ulcerative colitis patients were osteoporotic, with spine or femoral neck BMD T-score < -2.5. Spine BMD, and spine and femoral neck T-scores were lower and disease duration was longer in nine patients with ileal resection compared with nonoperated patients (0.84 +/- 0.15 g/cm2 vs 0.96 +/- 0.11 g/cm2, -3.0 +/- 1.5 vs -1.7 +/- 1.3, -3.2 +/- 1.5 vs -2.2 +/- 1.0, respectively; all p < 0.05). At 24 months, 13/36 (36%) and 14/36 (39%) patients experienced spinal and femoral neck bone loss, respectively, with mean annual percent BMD changes of -2.0% and -1.5%, respectively. NTx, a bone resorption marker, inversely correlated with spinal BMD rate of change (r = -0.4, p < 0.05). Using quartiles analysis, patients with the highest NTx (Q4) experienced the greatest decrease in spine BMD compared with patients with the lowest NTx (Q1).
CONCLUSIONS: Spine and femoral neck bone loss continues over time in more than one-third of IBD patients. Increased NTx level predicts spinal bone loss in IBD patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10710060     DOI: 10.1111/j.1572-0241.2000.01850.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

Review 1.  Metabolic bone disease in IBD.

Authors:  I Lopez; A L Buchman
Journal:  Curr Gastroenterol Rep       Date:  2000-08

2.  Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease.

Authors:  Sarah A Bartram; Robert T Peaston; David J Rawlings; David Walshaw; Roger M Francis; Nick P Thompson
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

3.  Sex-Specific Issues in Inflammatory Bowel Disease.

Authors:  Elizabeth Rosenblatt; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-09

Review 4.  Osteoporosis in young adults: pathophysiology, diagnosis, and management.

Authors:  S Ferrari; M L Bianchi; J A Eisman; A J Foldes; S Adami; D A Wahl; J J Stepan; M-C de Vernejoul; J-M Kaufman
Journal:  Osteoporos Int       Date:  2012-06-09       Impact factor: 4.507

Review 5.  Osteopenia and osteoporosis in gastrointestinal diseases: diagnosis and treatment.

Authors:  J C Southerland; J F Valentine
Journal:  Curr Gastroenterol Rep       Date:  2001-10

Review 6.  Neoplastic and other complications of inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2000-12

Review 7.  Clinical relevance of changes in bone metabolism in inflammatory bowel disease.

Authors:  Pal Miheller; Katalin Lorinczy; Peter-Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

Review 8.  Perspectives on osteoporosis in pediatric inflammatory bowel disease.

Authors:  Manisha Harpavat; David J Keljo
Journal:  Curr Gastroenterol Rep       Date:  2003-06

9.  Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease.

Authors:  Kylie E Whitten; Steven T Leach; Timothy D Bohane; Helen J Woodhead; Andrew S Day
Journal:  J Gastroenterol       Date:  2009-12-03       Impact factor: 7.527

10.  Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.

Authors:  Yuming Li; Zhongzhi Zhang; Xiuling Deng; Lulu Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.